Relapsed multiple myeloma presents a significant challenge in oncology, necessitating the development of novel therapeutic strategies.

The advent of targeted therapies, particularly those directed at B-cell maturation antigen (BCMA), has revolutionized treatment approaches, offering new hope for patients with relapsed or refractory disease.

BCMA-Targeted Therapies

BCMA is a protein expressed on the surface of malignant plasma cells in multiple myeloma. Targeting BCMA has become a focal point in the development of therapies aimed at eradicating myeloma cells while sparing healthy tissue.

Elranatamab (Elrexfio)

Elranatamab is a bispecific T-cell engager that targets both BCMA on myeloma cells and CD3 on T-cells, facilitating the immune system's ability to destroy malignant cells. Administered via subcutaneous injection, it has shown promise in clinical trials for patients with relapsed or refractory multiple myeloma. Common side effects include cytokine release syndrome, fatigue, and injection site reactions.

Idecabtagene Vicleucel (Abecma)

Idecabtagene vicleucel is a CAR T-cell therapy that involves modifying a patient's T-cells to express a receptor targeting BCMA. This personalized treatment has demonstrated significant efficacy in clinical trials, leading to its approval for patients with relapsed or refractory multiple myeloma. Side effects may include cytokine release syndrome, infections, and musculoskeletal pain.

Belantamab Mafodotin (Blenrep)

Belantamab mafodotin is an antibody-drug conjugate that targets BCMA and delivers a cytotoxicagent directly to the myeloma cells. While it has shown efficacy in clinical trials, its use is associated with ocular toxicities, including blurred vision and keratopathy. These side effects have led to its voluntary withdrawal from the market, although it remains an option in certain clinical settings.

Combination Therapies

Combining BCMA-targeted therapies with other agents has been explored to enhance treatment efficacy. For instance, combining elranatamab with agents like bortezomib or pomalidomide has been investigated to assess potential synergistic effects. These combination strategies aim to overcome resistance mechanisms and improve patient outcomes.

Challenges and Future Directions

Despite the advancements in BCMA-targeted therapies, challenges remain, including managing side effects, particularly ocular toxicities, and addressing the development of resistance. Ongoing research is focused on optimizing treatment regimens, exploring alternative targets, and developing strategies to mitigate adverse effects.

Additionally, the accessibility and cost of these therapies pose significant challenges, particularly in resource-limited settings. Efforts are underway to make these treatments more accessible to a broader patient population.

Conclusion

The landscape of relapsed multiple myeloma treatment has evolved with the introduction of BCMA-targeted therapies, offering new avenues for patients with limited options. Continued research and clinical trials are essential to further refine these therapies, manage associated risks, and improve patient outcomes in the fight against multiple myeloma.

::contentReference[oaicite:0]{index=0}